The Thrombocytopenia Market Insights report from DelveInsight provides a thorough understanding of the Thrombocytopenia Market size by treatment, epidemiology, emerging therapies, Thrombocytopenia market share of the various therapies, and the current and forecasted Thrombocytopenia Market size from 2019 to 2032 divided into the 7MM (the USA, EU5 (Germany, France, Italy, Spain, and the UK), and Japan) regions.

 

Thrombocytopenia: An Overview

Thrombocytopenia is a condition in which the blood has a lower than normal number of blood cell fragments called platelets. Platelets are made in the bone marrow along with other kinds of blood cells. They travel through the blood vessels and stick together (clot) to stop any bleeding that may happen if a blood vessel is damaged. Platelets also are called thrombocytes because a clot also is called a thrombus. When a patient’s blood has too few platelets, mild to serious bleeding can occur.

 

Download a sample copy of Thrombocytopenia report offering- https://www.delveinsight.com/sample-request/thrombocytopenia-market

 

Regions Covered in the Thrombocytopenia Market Report

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

 

Key Takeaways from Thrombocytopenia Market Report

• According to National Organization for Rare Disorders (NORD), prevalence of immune thrombocytopenia (ITP) is 9.5 cases per 100,000 and the annual prevalence is estimated at 5.3 per 100,000 among children. Worldwide, it is estimated that there are well over 200,000 people affected by ITP.
• As per Wu-Chi et al. (2019), the prevalence of ITP is 20.3 per 100,000 persons in the United States of America (USA) and 50.29 per 100,000 in the United Kingdom (UK).
• As per Kilpatrick Karynsa et al. (2021), in a retrospective cohort study of over 47,000 adult cancer patients treated with chemotherapy in outpatient oncology clinics across the United States, the prevalence of thrombocytopenia (platelet count ≤ 100 × 109/L) in all cancer patients across all chemotherapy regimens was 21%.
• According to DelveInsight’s analysis, In 2021, there were 3,982 and 63,752 cases, in the US, of ITP in Children between 0–17 years and in Adults of 18+ years, respectively.

 

Thrombocytopenia Epidemiology Insights 

The epidemiology section covers insights into the historical and current Thrombocytopenia Market patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.

 

Thrombocytopenia Epidemiology Segmentation in the 7MM

• ThrombocytopeniaPrevalent Cases
• ThrombocytopeniaIncident Cases
• Number of Cases of Heparin-Induced Thrombocytopenia
• Total Thrombocytopenia Epidemiology Cases

 

Thrombocytopenia Treatment Market

Thrombocytopenia treatment depends on its cause and severity. The main goal of treatment is to prevent death and disability caused by bleeding. If the condition is mild, the patient may not need treatment. A fully normal platelet count is not necessary to prevent bleeding, even with severe cuts or accidents.

 

Thrombocytopenia Market Insights

Thrombocytopenia can result from decreased platelet production, increased platelet consumption, or sequestration. A systematic approach should be used to evaluate incidental thrombocytopenia. Physicians should inquire about easy bruising or petechiae, melena, rashes, fevers, and bleeding during the patient’s history.

 

Thrombocytopenia Market Dynamics

The thrombocytopenia pipeline possesses potential drugs in mid-stage developments to be approved in the near future. The major key players include UCB Biopharma, Principia Biopharma, Baxalta/Takeda, Argenx, etc. hold the potential to create a significant positive shift in Thrombocytopenia market size.

 

Thrombocytopenia Emerging Therapies

• Tavalisse (RIGEL PHARMS INC)
• Cablivi (ABLYNX NV)
• Doptelet (AKARX INC)
• TAK-755 (Baxalta/Takeda)
• Rozanolixizumab (UCB Biopharma)
• Rilzabrutinib (Principia Biopharma), and several others

 

Thrombocytopenia Companies

• Sanofi (Ablynx)
• Rigel Pharmaceuticals/Kissei Pharmaceutical
• UCB Biopharma
• Principia Biopharma, and several others

 

Thrombocytopenia Drugs

• Cablivi (Caplacizumab/ALX-0081)
• Tavalisse (Fostamatinib)
• Doptelet (Avatrombopag)
• Mulpleta/Mulpleo (Lusutrombopag)
• Nplate (Romiplostim, AMG-531)
• Promacta (eltrombopag)

 

Get to know more about the research report- https://www.delveinsight.com/sample-request/thrombocytopenia-market

 

Table of content

1. Key Insights
2. Executive Summary
3. Competitive Intelligence Analysis
4. Thrombocytopenia Market Overview at a Glance
5. Disease Background and Overview
6. Patient Journey
7. Thrombocytopenia Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Unmet Needs
10. Key Endpoints of Thrombocytopenia Market Treatment
11. Marketed Products
12. Thrombocytopenia Emerging Therapies
13. Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview
17. KOL Views
18. Thrombocytopenia Market Drivers
19. Thrombocytopenia Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/